Compare Citius Pharmaceuticals Inc (CTXR) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NICE Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while NICE Ltd trades at $116.68 (market cap $6.81B). The key difference: NICE Ltd is far larger — about 500× Citius Pharmaceuticals Inc's market cap, and NICE Ltd is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and NICE Ltd for 15 Days on average.
| CTXR | NICE | |
|---|---|---|
Market Cap | $13.62M | $6.81B |
Volume | 132,438 | 382,395 |
Sector | Health | Technology |
52-Week High | $1.82 | $137.68 |
52-Week Low | $0.48 | $83.15 |
Typical Hold Time | 16 Days | 15 Days |
Enterprise Value | $3.79M | $6.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
NICE trades at $117.76, up 1.15% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding expectations. Recent news highlights leadership in AI-driven contact center platforms and workplace innovation awards, supporting positive sentiment.
The outlook for NICE is positive, driven by AI revenue growth and solid fundamentals, but risks include margin compression from heavy AI investments and competitive pressures. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
